Skip to search formSkip to main contentSkip to account menu

WHO Central Nervous System Grade III

Known as: Grade 3, Grade III, WHO Grade III 
Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs).
617Background: Currently, there is no published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials… 
2016
2016
Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).
274 Background: Angiogenesis is extensively developed in well-differentiated pancreatic neuroendocrine tumors (PNET) where… 
Review
2015
Review
2015
Treatment response and outcomes of grade 3 (G3) pancreatic neuroendocrine carcinomas (HGNEC) based on pathologic differentiation.
e15185 Background: World Health Organization criteria define HGNEC as neuroendocrine tumors with Ki-67 index > 20%. However, it… 
2013
2013
Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 loss.
Pilocytic astrocytoma (PA) is the most common pediatric tumor, with the vast majority being benign (WHO Grade I). Herein, we… 
2012
2012
Clear cells are associated with proliferative activity in ependymoma: a quantitative study.
Ependymomas comprise WHO Grade (G) II tumors (ependymomas) and WHO Grade III tumors (anaplastic ependymomas). Clear cell… 
2011
2011
Phase I study of temsirolimus (Tem) and pazopanib (Paz) in solid tumors with emphasis on renal cell carcinoma (RCC).
e15113 Background: Phase III trials have shown that either inhibition of VEGFR- (Paz) or mTOR-signaling (Tem) can improve… 
Review
2009
Review
2009
[Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer].
In performing FOLFOX chemotherapy (infusional 5-FU/LV with oxaliplatin) for advanced colorectal cancer, the neurotoxicity of… 
1996
1996
[Consideration of therapeutic choice for grade 3 superficial bladder cancer].
Between January, 1977 and December, 1994, 90 patients with grade 3 (G3) superficial bladder cancer were treated at Yokohama City… 
Review
1989
Review
1989
Chemical induction of brain tumors in rats by nitrosoureas: molecular biology and neuropathology.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)